Mirae Asset Global Investments Co. Ltd. Purchases 1,509 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Mirae Asset Global Investments Co. Ltd. grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 21.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,430 shares of the biotechnology company’s stock after purchasing an additional 1,509 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in ADMA Biologics were worth $163,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. USA Financial Formulas grew its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 539 shares during the period. Vontobel Holding Ltd. grew its position in shares of ADMA Biologics by 7.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after buying an additional 888 shares during the period. Quest Partners LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $29,000. Arizona State Retirement System raised its position in shares of ADMA Biologics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 61,641 shares of the biotechnology company’s stock valued at $689,000 after acquiring an additional 2,645 shares during the period. Finally, CWM LLC boosted its stake in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 4,367 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a report on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $15.50.

Insider Transactions at ADMA Biologics

In other news, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the sale, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock valued at $8,224,121 in the last ninety days. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Trading Up 18.8 %

ADMA opened at $19.37 on Monday. The stock has a market capitalization of $4.51 billion, a P/E ratio of 138.36 and a beta of 0.64. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. has a 12 month low of $3.40 and a 12 month high of $21.13. The firm’s fifty day simple moving average is $17.85 and its 200 day simple moving average is $13.46.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same period in the prior year, the firm earned ($0.02) earnings per share. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. As a group, research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.